Shulman L P
Department of Obstetrics and Gynecology, University of Illinois at Chicago, 60612-7313, USA.
Int J Fertil Womens Med. 2000 Mar-Apr;45(2):190-4.
Contraceptive options for women have expanded with the FDA approval of a monthly injectable contraceptive. Containing a progestin and estrogen (25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate; Lunelle/Lunella; Pharmacia and Upjohn), this novel once-a-month injection is characterized by the convenience and contraceptive efficacy of long-term reversible methods and the cycle control, return to fertility and side-effect profiles common to low-dose oral contraceptives. The association of these desirable attributes may increase the likelihood that a woman's chosen method will be used consistently and correctly to reduce the frequency of unintended pregnancy.
随着美国食品药品监督管理局（FDA）批准一种每月注射一次的避孕药物，女性的避孕选择有所增加。这种新型的每月注射一次的避孕药物含有一种孕激素和雌激素（25毫克醋酸甲羟孕酮和5毫克环丙孕酮雌二醇；Lunelle/Lunella；法玛西亚普强公司），其特点是具有长效可逆避孕方法的便利性和避孕效果，以及低剂量口服避孕药常见的周期控制、恢复生育能力和副作用特征。这些理想特性的结合可能会增加女性持续正确使用所选避孕方法的可能性，从而降低意外怀孕的发生率。
